299660 셀리드
기본 정보
- 섹터: KOSDAQ:일반서비스
- 시가총액: 414억원 (2026-06-30 기준)
- 첫 등장: 2026-06-26 (누적 1일)
- 태그: 매크로/바이오헬스 · 항암백신 · 면역치료 · CDMO · 바이오벤처 · 아데노바이러스벡터
- 네이버 금융: 🔗
기업개요
- 동사는 2006년 항암면역치료백신 및 COVID-19 예방백신 개발 전문 바이오벤처로 설립되어 2019년 코스닥에 상장함.
- CeliVax를 기반으로 항암면역치료백신과 아데노바이러스 벡터 기반 COVID-19 백신을 개발 중이고, 2020년 완공한 GMP시설로 CMO/CDMO 사업을 전개하고 있음.
- 2024년 포베이커를 소규모 합병하여 이커머스 사업부를 신설, 베이킹재료, 소모품, 기자재 등 온라인 식품 유통 판매업을 하고 있음.
출처: 네이버증권 종목분석 (WiseReport)
일자별 등장 (최신 위, 누적)
| 일자 | 전일 종가 | 종가 | 등락률 | 시간외 | vol | 색깔 | smart | 외 | 연 | 금투 | 투 | 개 | 그외 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-14 | 1,155 | 1,121 | 🔵 -2.94% | — | ×0.6 | 🟢 외인 | +1.1억 | +1.1 | +0.0 | +0.0 | +0.0 | -1.1 | +0.0 |
| 2026-07-13 | 1,255 | 1,155 | 🔵 -7.97% | — | ×0.7 | 🟢 외인 | +0.5억 | +0.5 | +0.0 | +0.0 | +0.0 | -0.5 | +0.0 |
| 2026-07-10 | 1,275 | 1,255 | 🔵 -1.57% | — | ×0.8 | 🔻 개인 | -0.9억 | -0.9 | +0.0 | -0.0 | +0.0 | +0.9 | +0.0 |
| 2026-07-09 | 1,345 | 1,275 | 🔵 -5.20% | — | ×0.6 | 🔻 개인 | -0.3억 | -0.3 | +0.0 | +0.0 | +0.0 | +0.3 | -0.1 |
| 2026-07-08 | 1,417 | 1,345 | 🔵 -5.08% | — | ×0.6 | 🔻 개인 | -0.8억 | -0.8 | +0.0 | +0.0 | +0.0 | +0.7 | +0.1 |
| 2026-07-07 | 1,430 | 1,417 | 🔵 -0.91% | — | ×0.4 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.1 | +0.0 |
| 2026-07-06 | 1,443 | 1,430 | 🔵 -0.90% | — | ×0.4 | 🔻 개인 | -0.4억 | -0.4 | +0.0 | +0.0 | +0.0 | +0.3 | +0.1 |
| 2026-07-03 | 1,427 | 1,443 | 🔴 +1.12% | — | ×0.6 | 🟢 외인 | +0.7억 | +0.7 | +0.0 | +0.0 | +0.0 | -0.6 | -0.1 |
| 2026-07-02 | 1,534 | 1,427 | 🔵 -6.98% | — | ×0.7 | 🔻 개인 | -1.0억 | -1.0 | +0.0 | +0.0 | +0.0 | +1.1 | -0.1 |
| 2026-07-01 | 1,406 | 1,534 | 🔴 +9.10% | — | ×2.8 | 🟢 외인 | +5.0억 | +5.0 | +0.0 | +0.0 | +0.0 | -5.2 | +0.3 |
| 2026-06-30 | 1,950 | 1,406 | 🔵 -27.90% | — | ×10.5 | 🔻 개인 | -0.8억 | -0.8 | +0.0 | +0.0 | +0.0 | +0.6 | +0.2 |
| 2026-06-29 | 2,785 | 1,950 | 🔵 -29.98% | — | ×0.9 | ⚫ 그외 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | -0.1 | +0.1 |
| 2026-06-26 | 2,430 | 2,785 | 🔴 +14.61% | — | ×2.2 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-06-25 | 2,430 | 2,430 | ⚪ +0.00% | — | ×0.6 | 🔻 개인 | -0.2억 | -0.2 | +0.0 | +0.0 | +0.0 | +0.2 | +0.0 |
| 2026-06-24 | 2,400 | 2,430 | 🔴 +1.25% | — | ×0.7 | 🔻 개인 | -0.8억 | -0.8 | +0.0 | +0.0 | +0.0 | +0.8 | +0.0 |
| 2026-06-23 | 2,675 | 2,400 | 🔵 -10.28% | — | ×1.2 | 🟢 외인 | +0.2억 | +0.2 | +0.0 | +0.0 | -0.2 | -0.0 | |
| 2026-06-22 | 2,760 | 2,675 | 🔵 -3.08% | — | ×1.0 | 🔻 개인 | -0.7억 | -0.7 | +0.0 | +0.0 | +0.7 | +0.0 | |
| 2026-06-19 | 2,620 | 2,760 | 🔴 +5.34% | — | ×3.5 | 🔻 개인 | -3.3억 | -3.3 | +0.0 | +0.0 | +3.3 | +0.0 | |
| 2026-06-18 | 2,705 | 2,620 | 🔵 -3.14% | — | ×0.7 | 🔻 개인 | -0.9억 | -0.9 | +0.0 | +0.0 | +0.9 | +0.0 | |
| 2026-06-17 | 2,470 | 2,705 | 🔴 +9.51% | — | ×1.6 | 🟢 외인 | +3.3억 | +3.3 | +0.0 | -2.2 | -1.1 | +0.0 | |
| 2026-06-16 | 2,480 | 2,470 | 🔵 -0.40% | — | ×0.4 | 🔻 개인 | -0.3억 | -0.3 | +0.0 | +0.0 | +0.3 | +0.0 | |
| 2026-06-15 | 2,535 | 2,480 | 🔵 -2.17% | — | ×0.5 | 🔻 개인 | -1.0억 | -1.0 | +0.0 | +0.0 | +1.0 | +0.0 | |
| 2026-06-12 | 2,395 | 2,535 | 🔴 +5.85% | — | ×0.5 | 🔻 개인 | -0.7억 | -0.7 | +0.0 | +0.0 | +0.7 | +0.0 | |
| 2026-06-11 | 2,390 | 2,395 | 🔴 +0.21% | — | ×0.5 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.1 | +0.0 | |
| 2026-06-10 | 2,490 | 2,390 | 🔵 -4.02% | — | ×0.6 | 🟢 외인 | +0.6억 | +0.6 | +0.0 | +0.0 | -0.6 | +0.0 | |
| 2026-06-09 | 2,545 | 2,490 | 🔵 -2.16% | — | ×0.6 | 🔻 개인 | -1.3억 | -1.3 | +0.0 | +0.0 | +1.3 | +0.0 | |
| 2026-06-08 | 2,765 | 2,545 | 🔵 -7.96% | — | ×0.7 | 🟢 외인 | +2.2억 | +2.2 | +0.0 | -0.0 | -2.2 | +0.0 | |
| 2026-06-05 | 2,855 | 2,765 | 🔵 -3.15% | — | ×0.2 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.1 | -0.0 | |
| 2026-06-04 | 2,800 | 2,855 | 🔴 +1.96% | — | ×0.2 | 🟢 외인 | +0.4억 | +0.4 | +0.0 | +0.0 | -0.4 | -0.1 | |
| 2026-06-02 | 2,775 | 2,800 | 🔴 +0.90% | — | ×0.3 | ⚫ 그외 | -0.0억 | -0.0 | +0.0 | +0.0 | -0.1 | +0.1 | |
| 2026-06-01 | 3,000 | 2,775 | 🔵 -7.50% | — | ×0.7 | 🟢 외인 | +0.3억 | +0.3 | +0.0 | -0.0 | -0.4 | +0.1 | |
| 2026-05-29 | 3,035 | 3,000 | 🔵 -1.15% | — | ×0.2 | 🔻 개인 | -0.4억 | -0.4 | +0.0 | +0.0 | +0.4 | +0.0 | |
| 2026-05-28 | 3,280 | 3,035 | 🔵 -7.47% | — | ×0.3 | 🔻 개인 | -2.1억 | -2.1 | +0.0 | +0.0 | +2.0 | +0.0 | |
| 2026-05-27 | 3,350 | 3,280 | 🔵 -2.09% | — | ×0.7 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.1 | |
| 2026-05-26 | 3,265 | 3,350 | 🔴 +2.60% | — | ×0.4 | 🟢 외인 | +0.5억 | +0.5 | +0.0 | +0.0 | -0.3 | -0.1 | |
| 2026-05-22 | 3,050 | 3,265 | 🔴 +7.05% | — | ×0.3 | 🟢 외인 | +2.8억 | +2.8 | +0.0 | +0.0 | -3.0 | +0.2 |
일자별 사유 (최신 위)
2026-06-26
- 사유: 코로나 백신 AdCLD-CoV19-1 OMI 3상 결과 공시 + 신규변이 수혜
- 섹터 컨텍스트: KOSDAQ:일반서비스 (smart -747억)
- 매크로 원인: 셀리드 코로나19 백신 3상 임상결과 공시 + 신규변이 BA.3.2.2 면역회피 이슈로 코로나 백신주 부각 (높음)